The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study

Abstract

Dysregulation in microRNA expression is a common feature in colorectal cancer. Due to the inconsistent results regarding serum miR-92a expression pattern and the insufficient studies on serum miR-375 and miR-760, we aimed in this study to investigate their expression profile and diagnostic and prognostic power in Egyptian colorectal cancer patients. The expression profile of miR-92a, miR-375, and miR-760 was determined in the sera of 64 colorectal cancer patients using quantitative real-time reverse transcription polymerase chain reaction in comparison to 27 healthy control subjects. The expression fold change of the studied microRNAs was correlated with patients' clinicopathological features. Receiver operating characteristic curve analysis was done to determine the role of these microRNAs in colorectal cancer diagnosis and follow-up according to the yielded area under the curve. The expression pattern of miR-92a was significantly upregulated (3.38 ± 2.52, p < 0.0001), while both of miR-375 and 760 were significantly downregulated (-1.250 ± 1.80, p< 0.0001; -1.710 ± 1.88, p < 0.0001, respectively) in colorectal cancer than the control. MiR-92a was positively correlated ( r = 0.671, p = 0.0001), while miR-375 and miR-760 were inversely correlated ( r = -0.414, p = 0.001; r = -0.644, p = 0.0001) with advanced colorectal cancer stages. Receiver operating characteristic curve analysis disclosed the highest diagnostic potential for miR-760 to discriminate colorectal cancer patients and early-stage colorectal cancer from the control (area under the curve = 0.922 and 0.875, respectively), while the highest prognostic potential for discrimination between colorectal cancer stages was for miR-92a. In conclusion, serum level of miR-92a, miR-375, and miR-760 may serve as biomarkers of colorectal cancer in Egyptian patients with high diagnostic power for miR-760 and high prognostic power for miR-92a.

Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia

“…Our results are in accordance with many other studies (Tanaka et al, 2009;Elhamamsy et al, 2017) who reported that mir-92a plasma levels were significantly lower in AML patients and also it was found to be very low in tumor tissues retrieved from patients with gastric cancer (Zhao et al, 2018), However, other studies found that suppression of miR-92a will induce apoptosis and can be considered as a novel method for treatment of Acute Promyelocytic Leukemia (Sharifi et al, 2014). Also, upregulation in miR-92a was observed in colorectal cancer (Elshafei et al, 2017) and cervical cancer (Zhou et al, 2015;Kawai et al, 2018).…”

miR‑760 mediates hypoxia-induced proliferation and apoptosis of human pulmonary artery smooth muscle cells via targeting TLR4

“…miR-760, a biomarker of colorectal cancer, is significantly downregulated in colorectal cancer and correlated with patient clinicopathological features ( 14 ). miR-760 also leads to epithelial-mesenchymal transition in breast cancer cells ( 15 ).…”

Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer

“…. Numerous studies have described the overexpression of miR-17 for another type of cancers, such as brain cancer (Gruszka and Zakrzewska, 2018), hepatocellular (Giray et al, 2014), and colon (Elshafei et al, 2017). The plasma expression level of miRNA-17 was raised at advanced NSCLC stages (Figure 1), but it did not lead to a statistically significant difference between two groups.…”